Patent Application
20220142885
The present invention primarily relates to fatty acid esters or mixtures or products comprising fatty acid esters as defined herein for use in the treatment of an excess of Malassezia on the skin surface of mammals, preferably of humans. The present invention further relates to particular mixtures or products, and to the cosmetic, non-therapeutic use of fatty acid esters or of mixtures or products comprising fatty acid esters as defined herein to reduce the amount of Malassezia on the skin surface of mammals, preferably of humans.
Further aspects of the present invention will arise from the description below, in particular from the examples, as well as from the attached patent claims.
Malassezia is a genus of fungi and is naturally found on the skin surfaces of many animals, including humans. It is involved in the pathogenesis of a variety of diseases, in particular skin diseases, and undesired conditions such as, for example, in Pityriasis versicolor (tinea versicolor), seborrheic dermatitis and dandruff.
Short-chain and medium-chain fatty acids display good antimicrobial activity against Malassezia. However, their practical use in topical therapy is limited by their (i) intense smell, (ii) skin irritation, (iii) lack of skin-substantiveness and (iv) the difficulties they pose during formulation into products.
Various esters of said fatty acids do not display these disadvantageous properties. It is known that Malassezia is able to cleave such esters and to release the fatty acids, which leads to a “self-kill” of the fungi. However, the hydrolysis rates of esters through Malassezia enzymes vary strongly depending on the alcohol component of the esters.
In DE 42 37 367 A1 fatty acid esters are described as antimycotic agents. These esters are preferably selected from the group of hexyl laurate, isopropyl stearate, glyceryl monolaurate, caprylic acid triglyceride and capric acid triglyceride. 1,3-Propanediol esters and glyceryl monoesters are not disclosed.
DE 42 34 188 A1 relates to ethoxylated and propoxylated organic compounds as antimycotic agents in cosmetics.
DE 10 2004 046 603 A1 describes substance mixtures comprising fatty acid esters of polyols and salts of short chain fatty acids to counteract microorganisms. It does not disclose any 1,3-propanediol esters and glyceryl monoesters.
SU 1286204 A1 discloses the use of a mixture of mono- (50-60%), di- (30-35%) and triesters (10-15%) of glycerol and undecylenic acid to give antimicrobial properties to a cosmetic base. 1,3-Propanediol esters as well as activity against Malassezia are not described.
DE 33 14 786 A1 discloses a mixture with antimycotic activity comprising mono and/or di-10-undecylenic acid glyceryl esters. The mixtures are used in the treatment of nasal cavity mycosis and onychomycosis. Their use for reducing the amount of Malassezia on the skin surface, preferably on the scalp, of mammals is not disclosed.
In WO 2006/054110 A2, esters of 1,2,3-propanetriol with one or more C11 to C24 fatty acids are described, wherein at least one fatty acid has at least one double bond. The application field for these substances is the treatment of chronic inflammatory disorders.
WO 2007/095262 A2 discloses 1,3-propanediol esters for the purpose of dissolving botanical extracts, fragrance concentrates and oils. Antimicrobial effects or benefits for skin and scalp of the 1,3-propanediol esters are not described.
It was thus an object of the present invention to provide more effective and compatible active agents for the treatment of Malassezia-associated diseases and undesired conditions, preferably of dandruff on human scalp.
According to a first aspect of the present invention, the stated object is achieved by a fatty acid ester or mixture of two or more fatty acid esters or mixture comprising one or more fatty acid esters, wherein the fatty acid ester or one, two, three or more, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate, glyceryl monocaprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate, preferably wherein the fatty acid ester or one, two or three, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate, glyceryl monocaprylate and 3-hydroxypropyl undecylenate, more preferably wherein the fatty acid ester or one or two, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate and 3-hydroxypropyl undecylenate, for use in the treatment of an excess of Malassezia on the skin surface, preferably on the scalp, of mammals, preferably of humans.
Within the framework of the present text, the term “Malassezia” refers to one or more species of the genus Malassezia, preferably to one, two, three, four, five or more species of the genus Malassezia (as defined further below).
Malassezia species are naturally found on the skin surfaces of many animals, including humans. As these fungi require fatty acids to grow, they are most common in areas with many sebaceous glands, i.e. on the scalp, face, and upper part of the body. However, when the fungus grows too rapidly, the natural renewal of cells is disturbed and, for example, dandruff appears on the scalp along with an itching sensation.
Within the framework of the present text, an excess of Malassezia on the skin surface, preferably on the scalp, of mammals, preferably of humans, thus relates to a situation where the total amount of Malassezia cells present on said skin surface leads to symptoms of skin disease such as, for example, redness, itching, dryness, flaking, greasiness, hypopigmentation and/or hyperpigmentation of the skin. The treatment of an excess of Malassezia on the skin surface preferably relates to an action that leads to a situation where the total amount of Malassezia cells present on said skin surface does not result in said symptoms of skin disease or wherein one, more or preferably all said symptoms are at least reduced.
Thus, preferably a use according to the present invention (as described herein) is selected from or comprises the treatment and/or the prevention of one, more or all symptoms from the group consisting of redness, itching, dryness, flaking, greasiness, hypopigmentation and hyperpigmentation of the skin.
Within the framework of the present text, the term “on the skin surface” also includes the areas of the hair infundibulum, the junctional zone and/or the sebaceous glands, if applicable, where an excess of Malassezia may be present.
Caprylate refers to an ester of caprylic acid (CAS Registry Number of caprylic acid: 124-07-2; also known as octanoic acid) and undecylenate refers to an ester of 10-undecylenic acid (CAS Registry Number of 10-undecylenic acid: 112-38-9; also known as 10-undecenoic acid). 3-Hydroxypropyl caprylate refers to the monoester of the alcohol 1,3-propanediol (CAS Registry Number: 504-63-2) with caprylic acid and 3-hydroxypropyl undecylenate refers to the monoester of the alcohol 1,3-propanediol with 10-undecylenic acid. Glyceryl monocaprylate refers to a monoester of (mono)glycerol (CAS Registry Number: 56-81-5; also known as 1,2,3-propanetriol) with caprylic acid and glyceryl monoundecylenate refers to a monoester of (mono)glycerol with undecylenic acid.
The investigations underlying the present invention surprisingly proved the rapid enzymatic release of caprylic acid and undecylenic acid from the fatty acid esters as defined herein by Malassezia strains involved in various undesired skin conditions, such as dandruff. It was particularly surprising to the expert in the field that Malassezia strains readily accept the fatty acid esters as defined herein as substrates, since the fatty acids caprylic acid and undecylenic acid are not found in sebum of the human skin. Moreover, since the hydrolysis rates of esters through Malassezia enzymes vary strongly depending on the alcohol component of the esters, it was also surprising that the fatty acid esters of 1,3-propanediol and glycerol were effectively hydrolysed by Malassezia.
A preferred embodiment of the invention relates to 3-hydroxypropyl caprylate or glyceryl monocaprylate or 3-hydroxypropyl undecylenate or glyceryl monoundecylenate or to a mixture comprising 3-hydroxypropyl caprylate or glyceryl monocaprylate or 3-hydroxypropyl undecylenate or glyceryl monoundecylenate (as the only Malassezia-active ingredient in the mixture) for use in the treatment of an excess of Malassezia on the skin surface, preferably on the scalp, of mammals, preferably of humans.
Another preferred embodiment of the invention relates to a mixture of 3-hydroxypropyl caprylate and 3-hydroxypropyl undecylenate, or of glyceryl monocaprylate and 3-hydroxypropyl undecylenate, or of 3-hydroxypropyl caprylate and glyceryl monoundecylenate, or of glyceryl monocaprylate and glyceryl monoundecylenate, or of 3-hydroxypropyl caprylate and glyceryl monocaprylate, or to a mixture comprising 3-hydroxypropyl caprylate and 3-hydroxypropyl undecylenate, or glyceryl monocaprylate and 3-hydroxypropyl undecylenate, or 3-hydroxypropyl caprylate and glyceryl monoundecylenate, or glyceryl monocaprylate and glyceryl monoundecylenate, or 3-hydroxypropyl caprylate and glyceryl monocaprylate (as the only Malassezia-active ingredients in the mixture) for use in the treatment of an excess of Malassezia on the skin surface, preferably on the scalp, of mammals, preferably of humans.
Another preferred embodiment of the invention relates to a mixture of 3-hydroxypropyl caprylate, glyceryl monocaprylate and 3-hydroxypropyl undecylenate, or to a mixture comprising 3-hydroxypropyl caprylate, glyceryl monocaprylate and 3-hydroxypropyl undecylenate (as the only Malassezia-active ingredients in the mixture) for use in the treatment of an excess of Malassezia on the skin surface, preferably on the scalp, of mammals, preferably of humans.
Another preferred embodiment of the invention relates to a mixture of 3-hydroxypropyl caprylate, glyceryl monocaprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate, or to a mixture comprising 3-hydroxypropyl caprylate, glyceryl monocaprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate (as the only Malassezia-active ingredients in the mixture) for use in the treatment of an excess of Malassezia on the skin surface, preferably on the scalp, of mammals, preferably of humans.
Another preferred embodiment of the invention relates to a fatty acid ester or mixture of two or more fatty acid esters or mixture comprising one or more fatty acid esters, wherein the fatty acid ester or one, two or three, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate for use in the treatment of an excess of Malassezia on the skin surface, preferably on the scalp, of mammals, preferably of humans. More preferably, the fatty acid esters and mixtures for use according to the invention (further) are not or do not comprise any diesters of caprylic acid and/or are not or do not comprise any triesters of caprylic acid and/or are not or do not comprise any ethoxylated variants of caprylic acid and/or are not or do not comprise any diesters of undecylenic acid and/or are not or do not comprise any triesters of undecylenic acid and/or are not or do not comprise any ethoxylated variants of undecylenic acid.
Advantageously, the fatty acid esters or mixtures for use as defined herein show particularly high antimicrobial activity against Malassezia. Particularly, binary combinations of fatty acid esters of caprylic acid and of fatty acid esters of undecylenic acid (as defined above) and mixtures comprising the same display a synergistic increase in antimicrobial activity against Malassezia (as will be demonstrated further below).
Another preferred embodiment of the invention relates to a mixture for use as defined herein, further comprising one or more 1,2-alkane diol(s), preferably one or more 1,2-alkane diol(s) selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol and 1,2-decanediol, more preferably one 1,2-alkane diol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol and 1,2-decanediol.
A preferred alternative embodiment relates to a fatty acid ester as defined herein for use as defined herein, which is used in combination with one or more 1,2-alkane diol(s), preferably one or more 1,2-alkane diol(s) selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol and 1,2-decanediol, more preferably one 1,2-alkane diol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol and 1,2-decanediol.
Surprisingly, it was found that the addition of one or more 1,2-alkane diol(s) as defined herein to one or more caprylic acid ester(s) or undecylenic acid ester(s) as defined herein, leads to a synergistic increase in antimicrobial activity against Malassezia (as will be demonstrated further below).
Thus, another preferred embodiment of the invention relates to a mixture comprising 1,2-pentanediol and 3-hydroxypropyl caprylate, or comprising 1,2-pentanediol and 3-hydroxypropyl undecylenate, or comprising 1,2-hexanediol and 3-hydroxypropyl caprylate, or comprising 1,2-hexanediol and 3-hydroxypropyl undecylenate, or comprising 1,2-octanediol and 3-hydroxypropyl caprylate, or comprising 1,2-octanediol and 3-hydroxypropyl undecylenate, or comprising 1,2-decanediol and 3-hydroxypropyl caprylate, or comprising 1,2-decanediol and 3-hydroxypropyl undecylenate, or comprising 1,2-pentanediol and glyceryl monocaprylate, or comprising 1,2-pentanediol and glyceryl monoundecylenate, or comprising 1,2-hexanediol and glyceryl monocaprylate, or comprising 1,2-hexanediol and glyceryl monoundecylenate, or comprising 1,2-octanediol and glyceryl monocaprylate, or comprising 1,2-octanediol and glyceryl monoundecylenate, or comprising 1,2-decanediol and glyceryl monocaprylate, or comprising 1,2-decanediol and glyceryl monoundecylenate, for use in the treatment of an excess of Malassezia on the skin surface, preferably on the scalp, of mammals, preferably of humans.
Another preferred embodiment relates to a fatty acid ester or a mixture for use as defined herein, wherein Malassezia is/are one or more species selected from the group consisting of M. furfur, M. pachydermatis, M. sympodialis, M. globosa, M. obtusa, M. restricta, M. slooffiae, M. dermatis, M. japonica, M. nana, M. yamatoensis, M. caprae, M. equina, M. cuniculi, M. brasiliensis, M. psitaci and M. arunalokei, preferably is/are selected from the group consisting of M. restricta, M. globosa, M. furfur, M. sympodialis and M. dermatis.
Another embodiment of the present invention relates to a mixture for use as defined herein, wherein the mixture comprising one or more fatty acid esters is a product selected from the group consisting of leave-on skin care product, preferably oil in water emulsion or water in oil emulsion, and rinse-off skin care product, preferably shampoo, more preferably anti-dandruff shampoo.
It is advantageous to formulate the mixtures for use as defined herein in a way that enables users to incorporate the treatment of an excess of Malassezia on their skin surface into their daily hair or skin care routine. This is achieved by, for example, formulating said mixtures as hair or skin care products. By creating hair or skin care products comprising one or more fatty acid esters for use as defined herein, e.g. an anti-dandruff shampoo, the user can save time, money and effort by combining the treatment against an excess of Malassezia on the skin surface with their standard hair or skin care, e.g. washing hair. The rinse-off skin care product as defined herein may also, for example, be a shower gel and the leave-on skin care product may, for example, be a body cream or body lotion.
Another preferred embodiment of the present invention relates to a mixture for use as defined herein, comprising one or more additional active agent(s), preferably one or more antimicrobial agent(s), more preferably one or more active agent(s) selected from the group consisting of clotrimazole (CAS Registry Number 23593-75-1), bifonazole (CAS Registry Number 60628-96-8), miconazole (CAS Registry Number 22916-47-8), ketoconazole (CAS Registry Number 65277-42-1), fluconazole (CAS Registry Number 86386-73-4), climbazole (CAS Registry Number 38083-17-9), itraconazole (CAS Registry Number 84625-61-6), terbinafine (CAS Registry Number 91161-71-6), nystatin (CAS Registry Number 1400-61-9), amorolfine (CAS Registry Number 78613-35-1), ciclopirox (CAS Registry Number 29342-05-0), octopirox (CAS Registry Number 68890-66-4) and undecylenic acid (CAS Registry Number 112-38-9).
A preferred alternative embodiment relates to a fatty acid ester for use as defined herein, which is used in combination with one or more additional active agent(s), preferably with one or more antimicrobial agent(s), more preferably with one or more active agent(s) selected from the group consisting of clotrimazole, bifonazole, miconazole, ketoconazole, fluconazole, climbazole, itraconazole, terbinafine, nystatin, amorolfine, ciclopirox, octopirox and undecylenic acid.
Another aspect of the present invention relates to a mixture, preferably a product selected from the group consisting of leave-on skin care product, preferably oil in water emulsion or water in oil emulsion, and rinse-off skin care product, preferably shampoo, more preferably anti-dandruff shampoo, comprising 3-hydroxypropyl caprylate and 3-hydroxypropyl undecylenate, or comprising glyceryl monocaprylate and 3-hydroxypropyl undecylenate, or comprising 3-hydroxypropyl caprylate and glyceryl monoundecylenate, or comprising glyceryl monocaprylate and glyceryl monoundecylenate, or comprising 3-hydroxypropyl caprylate and glyceryl monocaprylate.
According to a preferred embodiment, the total amount of the fatty acid ester(s) (as defined herein) comprised in the mixture or product as defined herein is from 0.02 to 5 wt.-%, more preferably from 0.05 to 2 wt.-%, most preferably from 0.1 to 1 wt.-%, relative to the total weight of said mixture or product.
According to another preferred embodiment, the weight ratio between the two fatty acid esters as defined herein comprised in the mixture or product as defined herein is from 10:1 to 1:10, more preferably from 5:1 to 1:5 and most preferably from 3:1 to 1:3.
Advantageously, mixtures and products comprising binary combinations of fatty acid esters of caprylic acid and of fatty acid esters of undecylenic acid as defined above display particularly high antimicrobial activity against Malassezia (as will be demonstrated further below).
According to an alternative embodiment, the present invention relates to a mixture, preferably product selected from the group consisting of leave-on skin care product, preferably oil in water emulsion or water in oil emulsion, and rinse-off skin care product, preferably shampoo, more preferably anti-dandruff shampoo, comprising a fatty acid ester or mixture of two or more fatty acid esters or mixture comprising one or more fatty acid esters, wherein the fatty acid ester or one, two, three or more, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate, glyceryl monocaprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate, preferably wherein the fatty acid ester or one, two or three, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate, glyceryl monocaprylate and 3-hydroxypropyl undecylenate, more preferably wherein the fatty acid ester or one or two, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate and 3-hydroxypropyl undecylenate.
According to a preferred alternative embodiment, the present invention relates to a mixture, preferably product selected from the group consisting of leave-on skin care product, preferably oil in water emulsion or water in oil emulsion, and rinse-off skin care product, preferably shampoo, more preferably anti-dandruff shampoo, comprising 3-hydroxypropyl caprylate, glyceryl monocaprylate and 3-hydroxypropyl undecylenate.
According to a particularly preferred alternative embodiment, the present invention relates to a mixture, preferably product selected from the group consisting of leave-on skin care product, preferably oil in water emulsion or water in oil emulsion, and rinse-off skin care product, preferably shampoo, more preferably anti-dandruff shampoo, comprising 3-hydroxypropyl caprylate, glyceryl monocaprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate.
A preferred embodiment relates to a mixture or product as defined herein, further comprising one or more 1,2-alkane diol(s), preferably one or more 1,2-alkane diol(s) selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol and 1,2-decanediol, more preferably one 1,2-alkane diol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol and 1,2-decanediol.
According to a preferred embodiment, the total amount of the fatty acid ester(s) (as defined herein) and 1,2-alkane diol(s) (as defined herein) comprised in the mixture or product as defined herein is from 0.1 to 10 wt.-%, more preferably from 0.2 to 5 wt.-%, most preferably from 0.3 to 3 wt.-%, relative to the total weight of said mixture or product.
According to another preferred embodiment, the weight ratio between the fatty acid ester(s) (as defined herein) and the 1,2-alkane diol(s) (as defined herein) comprised in the mixture or product as defined herein is from 20:1 to 1:20, more preferably from 10:1 to 1:10 and most preferably from 5:1 to 1:5.
Another preferred embodiment relates to a mixture, preferably a product selected from the group consisting of leave-on skin care product, preferably oil in water emulsion or water in oil emulsion, and rinse-off skin care product, preferably shampoo, more preferably anti-dandruff shampoo, comprising 1,2-pentanediol and 3-hydroxypropyl caprylate, or comprising 1,2-pentanediol and 3-hydroxypropyl undecylenate, or comprising 1,2-hexanediol and 3-hydroxypropyl caprylate, or comprising 1,2-hexanediol and 3-hydroxypropyl undecylenate, or comprising 1,2-octanediol and 3-hydroxypropyl caprylate, or comprising 1,2-octanediol and 3-hydroxypropyl undecylenate, or comprising 1,2-decanediol and 3-hydroxypropyl caprylate, or comprising 1,2-decanediol and 3-hydroxypropyl undecylenate, or comprising 1,2-pentanediol and glyceryl monocaprylate, or comprising 1,2-pentanediol and glyceryl monoundecylenate, or comprising 1,2-hexanediol and glyceryl monocaprylate, or comprising 1,2-hexanediol and glyceryl monoundecylenate, or comprising 1,2-octanediol and glyceryl monocaprylate, or comprising 1,2-octanediol and glyceryl monoundecylenate, or comprising 1,2-decanediol and glyceryl monocaprylate, or comprising 1,2-decanediol and glyceryl monoundecylenate.
It was surprisingly found that the addition of an 1,2-alkane diol as defined herein to a caprylic acid ester or undecylenic acid ester as defined herein leads to a synergistic increase in antimicrobial activity against Malassezia. Thus, the mixtures or products as defined herein display particularly high antimicrobial activity against Malassezia (as will be demonstrated further below).
Another preferred embodiment of the invention relates to a mixture or product as defined herein, comprising one or more additional active agent(s), preferably one or more antimicrobial agent(s), more preferably one or more active agent(s) selected from the group consisting of clotrimazole, bifonazole, miconazole, ketoconazole, fluconazole, climbazole, itraconazole, terbinafine, nystatin, amorolfine, ciclopirox, octopirox and undecylenic acid.
Another aspect of the present invention relates to a mixture or product as defined herein for use in the treatment of an excess of Malassezia on the skin surface, preferably on the scalp, of mammals, preferably of humans.
As defined above, an excess of Malassezia on the skin surface, preferably on the scalp, of mammals, preferably of humans, relates to a situation where the total amount of Malassezia cells present on said skin surface leads to symptoms of skin disease such as, for example, redness, itching, dryness, flaking, greasiness, hypopigmentation and/or hyperpigmentation of the skin.
A preferred embodiment relates to a mixture or product for use as defined herein, wherein Malassezia is/are one or more species selected from the group consisting of M. furfur, M. pachydermatis, M. sympodialis, M. globosa, M. obtusa, M. restricta, M. slooffiae, M. dermatis, M. japonica, M. nana, M. yamatoensis, M. caprae, M. equina, M. cuniculi, M. brasiliensis, M. psitaci and M. arunalokei, preferably is/are selected from the group consisting of M. restricta, M. globosa, M. furfur, M. sympodialis and M. dermatis.
Another preferred embodiment of the invention relates to a mixture or product for use as defined herein, comprising one or more additional active agent(s), preferably one or more antimicrobial agent(s), more preferably one or more active agent(s) selected from the group consisting of clotrimazole, bifonazole, miconazole, ketoconazole, fluconazole, climbazole, itraconazole, terbinafine, nystatin, amorolfine, ciclopirox, octopirox and undecylenic acid.
Another aspect of the present invention relates to a fatty acid ester or a mixture of two or more fatty acid esters or a mixture comprising one or more fatty acid esters, wherein the fatty acid ester or one, two, three or more, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate, glyceryl monocaprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate, preferably wherein the fatty acid ester or one, two or three, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate, glyceryl monocaprylate and 3-hydroxypropyl undecylenate, more preferably wherein the fatty acid ester or one or two, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate and 3-hydroxypropyl undecylenate, or a mixture or product as defined above for avoiding dandruff and/or for reducing the amount of dandruff on human skin, preferably on human scalp.
Within the framework of the present text, the term “avoiding dandruff on human skin, preferably on human scalp” relates to a preventive measure where the first occurrence or reoccurrence of dandruff on a defined area of human skin, preferably of human scalp, is avoided by applying the fatty acid esters or mixtures as defined herein once or repeatedly to said defined area of human skin. As a result, no dandruff is visible on said defined area of the human skin when inspected (by a trained professional in the field, such as e.g. a dermatologist) by naked human eye.
Within the framework of the present text, the term “reducing the amount of dandruff on human skin, preferably on human scalp” relates to a measure where the total amount of dandruff on a defined area of human skin, preferably of human scalp, as observed (by a trained professional in the field) by naked human eye is reduced by more than 10, 20, 30, 50, 60, 70, 80 or 90% after one-off or repeated treatment of said defined area with the fatty acid esters or mixtures as defined herein.
A preferred embodiment relates to 3-hydroxypropyl caprylate or glyceryl monocaprylate or 3-hydroxypropyl undecylenate or glyceryl monoundecylenate or to a mixture comprising 3-hydroxypropyl caprylate or glyceryl monocaprylate or 3-hydroxypropyl undecylenate or glyceryl monoundecylenate (as the only Malassezia-active ingredient in the mixture) for avoiding dandruff and/or for reducing the amount of dandruff on human skin, preferably on human scalp.
Another preferred embodiment of the present invention relates to a mixture of 3-hydroxypropyl caprylate and 3-hydroxypropyl undecylenate, or of glyceryl monocaprylate and 3-hydroxypropyl undecylenate, or of 3-hydroxypropyl caprylate and glyceryl monoundecylenate, or of glyceryl monocaprylate and glyceryl monoundecylenate, or of 3-hydroxypropyl caprylate and glyceryl monocaprylate, or to a mixture comprising 3-hydroxypropyl caprylate and 3-hydroxypropyl undecylenate, or glyceryl monocaprylate and 3-hydroxypropyl undecylenate, or 3-hydroxypropyl caprylate and glyceryl monoundecylenate, or glyceryl monocaprylate and glyceryl monoundecylenate, or 3-hydroxypropyl caprylate and glyceryl monocaprylate (as the only Malassezia-active ingredients in the mixture) for avoiding dandruff and/or for reducing the amount of dandruff on human skin, preferably on human scalp.
Another preferred embodiment of the present invention relates to a mixture of 3-hydroxypropyl caprylate, glyceryl monocaprylate and 3-hydroxypropyl undecylenate, or to a mixture comprising 3-hydroxypropyl caprylate, glyceryl monocaprylate and 3-hydroxypropyl undecylenate (as the only Malassezia-active ingredients in the mixture) for avoiding dandruff and/or for reducing the amount of dandruff on human skin, preferably on human scalp.
Another preferred embodiment of the present invention relates to a mixture of 3-hydroxypropyl caprylate, glyceryl monocaprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate, or to a mixture comprising 3-hydroxypropyl caprylate, glyceryl monocaprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate (as the only Malassezia-active ingredients in the mixture) for avoiding dandruff and/or for reducing the amount of dandruff on human skin, preferably on human scalp.
Another preferred embodiment of the invention relates to a fatty acid ester or mixture of two or more fatty acid esters or mixture comprising one or more fatty acid esters, wherein the fatty acid ester or one, two or three, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate for avoiding dandruff and/or for reducing the amount of dandruff on human skin, preferably on human scalp.
More preferably, fatty acid esters and mixtures for use according to the invention (further) are not or do not comprise any diesters of caprylic acid and/or are not or do not comprise any triesters of caprylic acid are not or do not comprise any ethoxylated variants of caprylic acid and/or are not or do not comprise any diesters of undecylenic acid and/or are not or do not comprise any triesters of undecylenic acid and/or are not or do not comprise any ethoxylated variants of undecylenic acid.
Another preferred embodiment relates to a mixture for use as defined above, wherein the mixture comprising one or more fatty acid esters is a product selected from the group consisting of leave-on skin care product, preferably oil in water emulsion or water in oil emulsion, and rinse-off skin care product, preferably shampoo, more preferably anti-dandruff shampoo.
Another preferred embodiment of the present invention relates to a mixture for use as defined herein, comprising one or more additional active agent(s), preferably one or more antimicrobial agent(s), more preferably one or more active agent(s) selected from the group consisting of clotrimazole, bifonazole, miconazole, ketoconazole, fluconazole, climbazole, itraconazole, terbinafine, nystatin, amorolfine, ciclopirox, octopirox and undecylenic acid.
A preferred alternative embodiment relates to a fatty acid ester for use as defined herein, which is used in combination with one or more additional active agent(s), preferably with one or more antimicrobial agent(s), more preferably with one or more active agent(s) selected from the group consisting of clotrimazole, bifonazole, miconazole, ketoconazole, fluconazole, climbazole, itraconazole, terbinafine, nystatin, amorolfine, ciclopirox, octopirox and undecylenic acid.
Another aspect of the present invention relates to the cosmetic, non-therapeutic use of a fatty acid ester or of a mixture of two or more fatty acid esters or of a mixture comprising one or more fatty acid esters, wherein the fatty acid ester or one, two, three or more, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate, glyceryl monocaprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate, preferably wherein the fatty acid ester or one, two or three, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate, glyceryl monocaprylate and 3-hydroxypropyl undecylenate, more preferably wherein the fatty acid ester or one or two, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate and 3-hydroxypropyl undecylenate, or of a mixture or product as defined above to reduce the amount of Malassezia on the skin surface, preferably on the scalp, of mammals, preferably of humans and/or to avoid dandruff and/or to reduce the amount of dandruff on human skin, preferably on human scalp.
As defined above, an excess of Malassezia on the skin surface of mammals, preferably of humans, relates to a situation where the total amount of Malassezia cells present on said skin surface leads to symptoms of skin disease such as, for example, redness, itching, dryness, flaking, greasiness, hypopigmentation and/or hyperpigmentation of the skin.
However, it may also be desirable to use the fatty acid ester(s) or mixtures as defined herein cosmetically/non-therapeutically to reduce the total amount of Malassezia cells on the skin surface, preferably on the scalp, of mammals, preferably of humans, in particular before a severe skin disease as described above develops. It is, for example, possible to use the fatty acid ester(s) or mixtures as defined herein to improve light symptoms of redness, itching, dryness, flaking, greasiness, hypopigmentation and/or hyperpigmentation of the skin, that would not (yet) be categorized as skin disease.
The term “to reduce the amount of Malassezia on the skin surface” as used within the present text is defined as a significant reduction of the total number of Malassezia cells on a defined area of skin surface of a mammal, preferably of a human, i.e. preferably a reduction of more than 10, 20, 30, 40, 50, 60, 70, 80 or 90% of the total number of Malassezia cells on a defined area of skin surface.
Within the framework of the present text, the term “to avoid dandruff on human skin, preferably on human scalp” relates to a preventive measure where the first occurrence or reoccurrence of dandruff on a defined area of human skin, preferably of human scalp, is avoided by applying the fatty acid esters or mixtures as defined herein once or repeatedly to said defined area of human skin. As a result, no dandruff is visible on said defined area of the human skin when inspected (by a trained professional in the field, such as e.g. a dermatologist) by naked human eye.
Within the framework of the present text, the term “to reduce the amount of dandruff on human skin, preferably on human scalp” relates to a measure where the total amount of dandruff on a defined area of human skin, preferably of human scalp, as observed (by a trained professional in the field) by naked human eye is reduced by more than 10, 20, 30, 50, 60, 70, 80 or 90% after one-off or repeated treatment of said defined area with the fatty acid esters or mixtures as defined herein.
Another embodiment of the invention relates to the cosmetic, non-therapeutic use as defined herein, wherein additionally to the fatty acid ester or to the mixture of two or more fatty acid esters or to the mixture comprising one or more fatty acid esters one or more 1,2-alkane diol(s), preferably of one or more 1,2-alkane diol(s) selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol and 1,2-decanediol, more preferably one 1,2-alkane diol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol and 1,2-decanediol, are used.
As outlined above, it was surprisingly found that the addition of an 1,2-alkane diol as defined herein to a caprylic acid ester or undecylenic acid ester as defined herein leads to a synergistic increase in antimicrobial activity against Malassezia.
Thus, another preferred embodiment of the invention relates to the cosmetic, non-therapeutic use of a mixture comprising 1,2-pentanediol and 3-hydroxypropyl caprylate, or comprising 1,2-pentanediol and 3-hydroxypropyl undecylenate, or comprising 1,2-hexanediol and 3-hydroxypropyl caprylate, or comprising 1,2-hexanediol and 3-hydroxypropyl undecylenate, or comprising 1,2-octanediol and 3-hydroxypropyl caprylate, or comprising 1,2-octanediol and 3-hydroxypropyl undecylenate, or comprising 1,2-decanediol and 3-hydroxypropyl caprylate, or comprising 1,2-decanediol and 3-hydroxypropyl undecylenate, or comprising 1,2-pentanediol and glyceryl monocaprylate, or comprising 1,2-pentanediol and glyceryl monoundecylenate, or comprising 1,2-hexanediol and glyceryl monocaprylate, or comprising 1,2-hexanediol and glyceryl monoundecylenate, or comprising 1,2-octanediol and glyceryl monocaprylate, or comprising 1,2-octanediol and glyceryl monoundecylenate, or comprising 1,2-decanediol and glyceryl monocaprylate, or comprising 1,2-decanediol and glyceryl monoundecylenate, to reduce the amount of Malassezia on the skin surface, preferably on the scalp, of mammals, preferably of humans.
Another embodiment of the invention relates to the cosmetic, non-therapeutic use as defined herein, wherein Malassezia is/are one or more species selected from the group consisting of M. furfur, M. pachydermatis, M. sympodialis, M. globosa, M. obtusa, M. restricta, M. slooffiae, M. dermatis, M. japonica, M. nana, M. yamatoensis, M. caprae, M. equina, M. cuniculi, M. brasiliensis, M. psitaci and M. arunalokei, preferably is/are selected from the group consisting of M. restricta, M. globosa, M. furfur, M. sympodialis and M. dermatis.
Another embodiment of the invention relates to the cosmetic, non-therapeutic use as defined herein, wherein the mixture comprising one or more fatty acid esters is a product selected from the group consisting of leave-on skin care product, preferably oil in water emulsion or water in oil emulsion, and rinse-off skin care product, preferably shampoo, more preferably anti-dandruff shampoo.
Another embodiment of the invention relates to the cosmetic, non-therapeutic use as defined herein, wherein additionally to the fatty acid ester or to the mixture of two or more fatty acid esters or to the mixture comprising one or more fatty acid esters and, optionally to the one or more 1,2-alkane diol(s), one or more additional active agent(s), preferably one or more antimicrobial agent(s), more preferably one or more active agent(s) selected from the group consisting of clotrimazole, bifonazole, miconazole, ketoconazole, fluconazole, climbazole, itraconazole, terbinafine, nystatin, amorolfine, ciclopirox, octopirox and undecylenic acid is/are used.
A method for reducing the amount of Malassezia on the skin surface, preferably on the scalp, of mammals, preferably of humans, in particular of humans in need thereof (i.e. of humans showing one or more symptoms of skin disease such as, for example, redness, itching, dryness, flaking, greasiness, hypopigmentation and/or hyperpigmentation of the skin) comprising or consisting of the step of applying a fatty acid ester or a mixture of two or more fatty acid esters or a mixture comprising one or more fatty acid esters, wherein the fatty acid ester or one, two, three or more, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate, glyceryl monocaprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate, or of applying a mixture or product as defined herein to the skin surface, preferably to the scalp, of a mammal, preferably of a human, is also disclosed within the framework of the present text.
A preferred embodiment relates to a method as defined above, wherein the applied fatty acid ester or one, two or three, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate, glyceryl monocaprylate and 3-hydroxypropyl undecylenate.
Another preferred embodiment relates to a method as defined above, wherein the applied fatty acid ester or one, two or three, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate.
Another preferred embodiment relates to a method as defined above, wherein the applied fatty acid ester or one or two, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate and 3-hydroxypropyl undecylenate.
Another preferred embodiment relates to a method as defined above, wherein the applied fatty acid ester is 3-hydroxypropyl caprylate or glyceryl monocaprylate or 3-hydroxypropyl undecylenate or glyceryl monoundecylenate or wherein the applied mixture comprises 3-hydroxypropyl caprylate or glyceryl monocaprylate or 3-hydroxypropyl undecylenate or glyceryl monoundecylenate (as the only Malassezia-active ingredient in the mixture).
Another preferred embodiment relates to a method as defined above, wherein the applied mixture is 3-hydroxypropyl caprylate and 3-hydroxypropyl undecylenate, or is glyceryl monocaprylate and 3-hydroxypropyl undecylenate, or is 3-hydroxypropyl caprylate and glyceryl monoundecylenate, or is glyceryl monocaprylate and glyceryl monoundecylenate, or is 3-hydroxypropyl caprylate and glyceryl monocaprylate, or wherein the applied mixture comprises 3-hydroxypropyl caprylate and 3-hydroxypropyl undecylenate, or comprises glyceryl monocaprylate and 3-hydroxypropyl undecylenate, or comprises 3-hydroxypropyl caprylate and glyceryl monoundecylenate, or comprises glyceryl monocaprylate and glyceryl monoundecylenate, or comprises 3-hydroxypropyl caprylate and glyceryl monocaprylate (as the only Malassezia-active ingredients in the mixture).
Another preferred embodiment relates to a method as defined above, wherein the applied mixture is 3-hydroxypropyl caprylate, glyceryl monocaprylate and 3-hydroxypropyl undecylenate, or wherein the applied mixture comprises 3-hydroxypropyl caprylate, glyceryl monocaprylate and 3-hydroxypropyl undecylenate (as the only Malassezia-active ingredients in the mixture).
Another preferred embodiment relates to a method as defined above, wherein the applied mixture is 3-hydroxypropyl caprylate, glyceryl monocaprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate, or wherein the applied mixture comprises 3-hydroxypropyl caprylate, glyceryl monocaprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate (as the only Malassezia-active ingredients in the mixture).
More preferably, the applied fatty acid esters or mixtures in the method as defined above (further) are not or do not comprise any diesters of caprylic acid and/or are not or do not comprise any triesters of caprylic acid are not or do not comprise any ethoxylated variants of caprylic acid and/or are not or do not comprise any diesters of undecylenic acid and/or are not or do not comprise any triesters of undecylenic acid and/or are not or do not comprise any ethoxylated variants of undecylenic acid.
Another embodiment relates to a method as defined above, wherein Malassezia is/are one or more species selected from the group consisting of M. furfur, M. pachydermatis, M. sympodialis, M. globosa, M. obtusa, M. restricta, M. slooffiae, M. dermatis, M. japonica, M. nana, M. yamatoensis, M. caprae, M. equina, M. cuniculi, M. brasiliensis, M. psitaci and M. arunalokei, preferably is/are selected from the group consisting of M. restricta, M. globosa, M. furfur, M. sympodialis and M. dermatis.
Another embodiment relates to a method as defined above, wherein the mixture comprising one or more fatty acid esters is a product selected from the group consisting of leave-on skin care product, preferably oil in water emulsion or water in oil emulsion, and rinse-off skin care product, preferably shampoo, more preferably anti-dandruff shampoo.
Another embodiment relates to a method as defined above, wherein the applied mixture or product as defined herein comprises one or more additional active agent(s), preferably one or more antimicrobial agent(s), more preferably one or more active agent(s) selected from the group consisting of clotrimazole, bifonazole, miconazole, ketoconazole, fluconazole, climbazole, itraconazole, terbinafine, nystatin, amorolfine, ciclopirox, octopirox and undecylenic acid.
A preferred alternative embodiment relates to a method as defined above, wherein the fatty acid ester as defined herein is applied in combination with one or more additional active agent(s), preferably with one or more antimicrobial agent(s), more preferably with one or more active agent(s) selected from the group consisting of clotrimazole, bifonazole, miconazole, ketoconazole, fluconazole, climbazole, itraconazole, terbinafine, nystatin, amorolfine, ciclopirox, octopirox and undecylenic acid.
(Preferred) embodiments of the fatty acid esters or mixtures or products for use according to the invention correspond to or can be derived from the (preferred) embodiments of the mixtures or products or uses according to the invention or from the (preferred) embodiments of the method as described herein, which are explained above, or vice versa.
The invention will now be described in more detail hereinafter with references to selected examples.
The fatty acid esters and their mixtures were tested for growth inhibition against Malassezia. The following reference strains were included:
M. furfur
M. sympodialis
M. globosa
M. restricta
M. pachydermatis
Tests were performed on solid media using agar dilution tests. Stock solutions of test substances were prepared in mDixon-Agar (cf. Table 2). Lower test concentrations were obtained by diluting stock solutions with fresh agar.
Preparation of liquid agar was carried out in temperated water bath. Required amounts of test substances were weighed in 130 ml of Dixon Agar and mixed with fresh Dixon-Agar to reach desired concentrations of test substances. Agar solutions with test substances were then poured into 24 well-plates. The pH value in all assays was maintained at 5.5. Preparation of test substances was done on weight per volume base. All results are expressed in parts per million (1 ppm=0.0001%).
Microbial test strains were prepared according to the procedure described by Mayser (Mayser P., Medium chain fatty acid ethyl esters—activation of antimicrobial effects by Malassezia enzymes. Mycoses 2015; 58:215-9). Briefly, Malassezia strains were cultivated on selective agar for pathogenic fungi (Merck) and overlaid with a thin layer of cold-sterilized olive oil. Cell counts were determined in a Neubauer chamber and 1.75×106 cells suspended in 20 μl olive oil transferred to the test plates (corresponds to 106 cells per cm2). Incubation was carried out at 32° C. over a maximal duration of 14 days with regular inspection and documentation of growth status. Minimal inhibitory concentrations (MICs) were determined as the lowest concentrations of test compound without visible growth. Each experiment was repeated to confirm results.
Minimal inhibitory concentrations for test substances were determined for the different test strains (Table 3, 4, 5). As reference substances, the pure acids caprylic acid and undecylenic acid were used.
M.
M.
M. furfur
M. sympodialis
M. globosa
restricta
pachydermatis
The results in Table 3 demonstrate that monoesters of caprylic and undecylenic acid with either 1,3-propanediol or glycerol are highly active against a broad spectrum of Malassezia strains inhabiting human and animal skin.
M.
M.
M. furfur
M. sympodialis
M. globosa
restricta
pachydermatis
The results in Table 4 show that diesters or ethoxylated variants of caprylic acid are not or only partially active against Malassezia strains.
M. furfur
M. globosa
M. restricta
M. pachydermatis
The results in Table 5 show that diesters, triesters or ethoxylated variants of undecylenic acid are not or only partially active against Malassezia strains.
Additionally, MIC-values for various alkane diols were determined (Table 6).
Malassezia test strains)
M. sympodialis
M. globosa
M. restricta
Subsequently, binary mixtures of caprylic acid and undecylenic acid esters were prepared (Table 7) and MIC-values determined as described above (Table 8).
Synergistic antimicrobial effects were determined by calculation of Synergy Indices (SI) according to Kull's equation (I) (Kull, F. C., Eismann, P. C., Sylvestrowicz, H. D., and R. L. Mayer (1961). Mixtures of Quaternary Ammonium Compounds and Long-chain Fatty Acids as Antifungal Agents. Applied Microbiology 9, 538-541. Steinberg, D. C. (2000). Measuring Synergy. Cosmetics & Toiletries 115 (11), 59-62).
SI=(Cmixture×PA)/CA+(Cmixture×PB)/CB (I)
where
SI is the Synergy Index according to Kull
CA is the cell count for substance A
CB is the cell count for substance B
Cmixture is the cell count for the mixture of substances A and B
PA is the proportion of the substance A in the mixture
PB is the proportion of the substance B in the mixture.
SI-values below 1 indicate synergistic activity of test substances.
M.
M.
M. furfur
M. sympodialis
M. globosa
restricta
pachydermatis
1)MIC-values <100 were set to 50 for SI-calculation
In a further experiment, binary mixtures of caprylic acid esters and undecylenic acid esters, respectively, with alkane diols were prepared (Table 9) and MIC-values determined as described above (Table 10). Synergistic antimicrobial effects were determined by calculation of Synergy Indices (SI) according to Kull's equation as described above.
M. sympodialis
M. globosa
M. restricta
1)MIC-values <100 were set to 50 for SI-calculation
The two substances 3-hydroxypropyl caprylate and 3-hydroxypropyl undecylenate have shown outstanding activity against different Malassezia species and strains. For these two substances ester cleavage by M. globose and M. restricta lipases and hydrolases and subsequent liberation of free fatty acids was demonstrated.
It is well known in the art that free short- and mid-chain saturated fatty acids, for example capric acid (C10:0), caprylic acid (C8:0), and capronic acid (C6:0) show antimicrobial activity. Use of these free fatty acids for treating Malassezia-associated conditions and diseases in cosmetic or medical products are hampered by their intense, negatively perceived odour and their irritating potential at higher concentrations.
Surprisingly it was found that a similar antimicrobial effect can be obtained against Malassezia spp., but not Candida spp., when monoesters of these fatty acids are used. This highly specific effect is facilitated by Malassezia lipases and hydrolases, which cleave the esters and thereby liberate the active principle of the fatty acid. This results in a targeted activation of the antimicrobial molecules only in local areas of the skin, where Malassezia density is high.
For esters of monohydric alcohols, cleavage by Malassezia spp. has been demonstrated before. Esters of monohydric alcohols (e.g. methanol, ethanol, propanol, isopropanol etc.), however, are less active against different Malassezia species and also have the severe disadvantage of strong odour, which limits their use to low concentrations.
During the studies underlying the present invention, experimental proof of ester cleavage for 3-hydroxypropyl caprylate and 3-hydroxypropyl undecylenate was demonstrated for the two species M. globosa and M. restricta (cf. Table 11). These two species are the most frequently detected ones on human scalp and skin and their hydrolytic/lipolytic activities on fatty acid esters has not yet been investigated before.
Malassezia strains used for the experiments on ester cleavage
M. restricta
M. globosa
Malassezia strains were cultivated on selective agar for pathogenic fungi (Merck) and overlaid with a thin layer of cold-sterilized olive oil. After 3 to 5 days, fungal cells were harvested and resuspended in the respective test substance. Cell numbers were determined using a Neubauer counting chamber (cf. Table 12). Sterile Petri dishes (diameter: 3 cm) were prepared containing selective agar for pathogenic fungi, overlaid with 100 μl of the test suspensions and incubated at 32° C.
M. globosa CBS
M. restricta CBS
After defined incubation times (0, 3, 6, 12, 24, 48, and 72 h), test suspensions were removed from the agar surface by rinsing with 1 ml chloroform and stored under cool conditions in gastight tubes until analysis. Chloroform was removed by evaporation at 30° C. in the fume hood and the remaining liquid mixed with 1 ml isopropanol, transferred in Eppendorf tubes and centrifuged. The supernatant was transferred to new Eppendorf tubes.
In order to analytically quantify esters and free fatty acid resulting from cleavage by Malassezia enzymes, gas chromatography was used.
For quantification (range 0.1-10 wt %) a multilevel calibration method with internal standard (ISTD, docosane [C22]; 500 mg in MtBE) was used. An equal amount of corresponding acid, ester and possible side products [0.2-50 mg/10 mL] were mixed with ISTD, diluted to an appropriate concentration and 1 μL [split1:50] was directly used for GC-analysis with the following conditions: GC Agilent 6890 with a 20 m ZB-Wax column [0.20 mm×0.20 μm], injector temperature of 250° C., detector temperature of 275° C., flow gas of 1.3 mL/min hydrogen [constant]. For temperature profile 60° C. to 240° C. with a heating rate of 9° C./min was used.
3-Hydroxypropyl caprylate was rapidly cleaved to caprylic acid and 1,3-propanediol by the two Malassezia strains. With M. globosa CBS 7705, 75% of the ester was cleaved after 6 hours and 90% was cleaved after 12 hours (
3-Hydroxypropyl undecylenate was accepted as a preferred substrate by Malassezia enzymes, as well, leading to fast generation of undecylenic acid. Incubating M. globosa CBS 7705 together with this substance resulted in 95% cleavage after 6 hours and 99.5% cleavage after 12 hours (
The perfume oils P01, P02, P03, PO4, or P05 from the above examples were worked separately in each case into the formulations presented below.
Cosmetic formulations (compositions)—amounts are indicated as % by weight for all formulations.
Mauritia Flexuosa Fruit Oil
Theobroma Cacao (Cocoa) Seed Butter
Butyrospermum Parkii (Shea) Butter
Echinacea Purpurea Extract
Alba)
Virginiana (Witch Hazel) Water, Water
Helianthus Amuus (Sunflower) Seed
Prunus dulcis
An in vivo study was performed to investigate the potential of 3-hydroxypropyl caprylate for anti-dandruff efficacy on scalp. The efficacy was assessed based on the dandruff score according to Piérard-Franchimont, which evaluates the dandruff intensity on a scale from 0-10 (0=none; 1-2=mild; 3-4=moderate; 5-6=marked; 7-8=severe; 9-10=heavy) for 8 individual sections of the scalp. 22 participants with a visual dandruff score of 32 (sum of score over all 8 sections) were included in the study.
The active ingredient was provided in a leave-on pump spray (formulation of 0.5 wt.-% of 3-hydroxypropyl caprylate in ethanol/water 70/30 vol/vol). After two weeks of wash out with an active free shampoo, the test product was applied once daily to the scalp (30 spray bursts, every evening, leave-on overnight) for four weeks, while washing with the active free shampoo continued as during the first two weeks of wash out.
The dandruff scoring was performed after the two weeks of wash out with active free shampoo by a trained technician on day 1 (before first use of the active-containing leave on-pump spray) and day 29 of the treatment with the leave-on pump spray and is depicted in
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2019/052576 | 2/4/2019 | WO | 00 |
